Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis
ConclusionIn the short and long term, upadacitinib combination therapy versus tofacitinib combination therapy and upadacitinib monotherapy versus methotrexate monotherapy were associated with significantly lower direct medical costs for patients with RA.Trial RegistrationClinicalTrials.gov identifier, NCT02675426, NCT02706951, and NCT00853385.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Arthritis | Drugs & Pharmacology | Men | Methotrexate | Rheumatoid Arthritis | Rheumatology